Literature DB >> 18837082

Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas.

Bo Zhai1, He-Xin Yan, Shu-Qin Liu, Lei Chen, Meng-Chao Wu, Hong-Yang Wang.   

Abstract

AIM: To examine the immunoreactivity of E-cadherin and four subtypes of catenin family in human hepatocellular carcinomas (HCCs) and to investigate the correlation between expression of E-cadherin/catenin complex and clinicopathologic parameters of HCC patients.
METHODS: An immunohistochemical study for E-cadherin and catenins was performed on 97 formalin-fixed, paraffin-embedded specimens of HCC.
RESULTS: Reduced expression of E-cadherin, alpha-, beta-, gamma-catenin and p120 was observed in 69%, 76%, 63%, 71% and 73%, respectively. Both expressions of E-cadherin and catenin components were significantly correlated with tumor grade (P = 0.000). It showed significant difference between expression of catenin members and tumor stage (P = 0.003, P = 0.017, P = 0.007 and P = 0.000, respectively). The reduced expression of E-cadherin in HCCs was significantly correlated with intrahepatic metastasis (IM) and capsular invasion (P = 0.008, P = 0.03, respectively). A close correlation was also observed between the expression of catenins and the tumor size (P = 0.002, P = 0.034, P = 0.016 and P = 0.000, respectively). In addition, the expression of each catenin was found correlated with IM (P = 0.012, P = 0.049, P = 0.026 and P = 0.014, respectively). No statistically significant difference was observed between the expression level of E-cadherin/catenin complex and lymph node permission, vascular invasion and satellite nodules. Interestingly, only expression of p120 showed correlation with AFP value (P = 0.035). The expression of E-cadherin was consistent with alpha-, beta-, gamma-catenin and p120 expression (P = 0.000). Finally, the abnormal expression of E-cadherin/catenin complex was significantly associated with patients' survival (P = 0.0253, P = 0.0052, P = 0.003, P = 0.0105 and P = 0.0016, respectively). Nevertheless, no component of E-cadherin/catenin complex was the independent prognostic factor of HCC patients.
CONCLUSION: Down-regulated expressions of E-cadherin, catenins and p120 occur frequently in HCCs and contribute to the progression and development of tumor. It may be more exact and valuable to detect the co-expression of E-cadherin/catenin complex than to explore one of them in predicting tumor invasion, metastasis and patient's survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837082      PMCID: PMC2748200          DOI: 10.3748/wjg.14.5665

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

1.  Proliferative activity in intrahepatic metastasis of hepatocellular carcinoma.

Authors:  T Maeda; E Adachi; K Kajiyama; K Takenaka; K Sugimachi; M Tsuneyoshi
Journal:  J Gastroenterol Hepatol       Date:  1996-08       Impact factor: 4.029

2.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Authors:  Sandrine Boyault; David S Rickman; Aurélien de Reyniès; Charles Balabaud; Sandra Rebouissou; Emmanuelle Jeannot; Aurélie Hérault; Jean Saric; Jacques Belghiti; Dominique Franco; Paulette Bioulac-Sage; Pierre Laurent-Puig; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

3.  Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas.

Authors:  A Ihara; H Koizumi; R Hashizume; T Uchikoshi
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

4.  Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis.

Authors:  Jik Young Park; Won Sang Park; Suk Woo Nam; Su Young Kim; Sug Hyung Lee; Nam Jin Yoo; Jung Young Lee; Cheol Keun Park
Journal:  Liver Int       Date:  2005-02       Impact factor: 5.828

5.  Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival.

Authors:  J Paredes; A L Correia; A S Ribeiro; F Milanezi; J Cameselle-Teijeiro; F C Schmitt
Journal:  J Clin Pathol       Date:  2008-04-01       Impact factor: 3.411

6.  Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.

Authors:  Young-Dae Kim; Chang-Hwan Park; Hyun-Soo Kim; Sung-Kyu Choi; Jong-Sun Rew; Dong-Yi Kim; Yang-Suk Koh; Kyung-Woon Jeung; Kyung-Hwa Lee; Ji-Shin Lee; Sang-Woo Juhng; Jae-Hyuk Lee
Journal:  J Gastroenterol Hepatol       Date:  2008-01       Impact factor: 4.029

7.  Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis.

Authors:  A Lugli; I Zlobec; P Minoo; K Baker; L Tornillo; L Terracciano; J R Jass
Journal:  Histopathology       Date:  2007-03       Impact factor: 5.087

Review 8.  Molecular pathways and related target therapies in liver carcinoma.

Authors:  S Tommasi; R Pinto; B Pilato; A Paradiso
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

9.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.

Authors:  A de La Coste; B Romagnolo; P Billuart; C A Renard; M A Buendia; O Soubrane; M Fabre; J Chelly; C Beldjord; A Kahn; C Perret
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

Review 10.  From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.

Authors:  Roberta W C Pang; Ronnie T P Poon
Journal:  Oncology       Date:  2007-12-13       Impact factor: 2.935

View more
  46 in total

1.  Prognostic relevance of β-catenin expression in T2-3N0M0 esophageal squamous cell carcinoma.

Authors:  Dong-Rong Situ; Yi Hu; Zhi-Hua Zhu; Jian Wang; Hao Long; Tie-Hua Rong
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

Review 2.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

Review 3.  Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.

Authors:  Reem Malek; Hailun Wang; Kekoa Taparra; Phuoc T Tran
Journal:  Cells Tissues Organs       Date:  2017-02-20       Impact factor: 2.481

4.  Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells.

Authors:  Lili Wang; Lexun Xue; Hongxia Yan; Jie Li; Yucheng Lu
Journal:  Mol Biol Rep       Date:  2009-08-02       Impact factor: 2.316

Review 5.  E-cadherin's dark side: possible role in tumor progression.

Authors:  Fausto J Rodriguez; Laura J Lewis-Tuffin; Panos Z Anastasiadis
Journal:  Biochim Biophys Acta       Date:  2012-03-13

6.  Mice with Hepatic Loss of the Desmosomal Protein γ-Catenin Are Prone to Cholestatic Injury and Chemical Carcinogenesis.

Authors:  Lili Zhou; Tirthadipa Pradhan-Sundd; Minakshi Poddar; Sucha Singh; Alex Kikuchi; Donna B Stolz; Weinian Shou; Zongfang Li; Kari N Nejak-Bowen; Satdarshan P Monga
Journal:  Am J Pathol       Date:  2015-10-17       Impact factor: 4.307

7.  Screening candidate metastasis-associated genes in three-dimensional HCC spheroids with different metastasis potential.

Authors:  Rongxin Chen; Yinying Dong; Xiaoying Xie; Jie Chen; Dongmei Gao; Yinkun Liu; Zhenggang Ren; Jiefeng Cui
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 8.  miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.

Authors:  Weiqi Tan; Yang Li; Seng-Gee Lim; Theresa M C Tan
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

9.  Intersecting pathways in inflammation and cancer: Hepatocellular carcinoma as a paradigm.

Authors:  Philip Y Wai; Paul C Kuo
Journal:  World J Clin Oncol       Date:  2012-02-10

10.  Transducin (Beta)-Like 1 X-Linked Receptor 1 Correlates with Clinical Prognosis and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.

Authors:  Xuejun Kuang; Jiye Zhu; Zhao Peng; Jianjun Wang; Zhigang Chen
Journal:  Dig Dis Sci       Date:  2015-09-19       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.